Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Anderson-Fabry disease in children.

Sestito S, Ceravolo F, Concolino D.

Curr Pharm Des. 2013;19(33):6037-45. Review.

PMID:
23448455
2.

Anderson-Fabry disease: a multiorgan disease.

Tuttolomondo A, Pecoraro R, Simonetta I, Miceli S, Pinto A, Licata G.

Curr Pharm Des. 2013;19(33):5974-96. Review.

PMID:
23448451
3.

Neurological complications of Anderson-Fabry disease.

Tuttolomondo A, Pecoraro R, Simonetta I, Miceli S, Arnao V, Licata G, Pinto A.

Curr Pharm Des. 2013;19(33):6014-30. Review.

PMID:
23448452
4.

Renal complications of Fabry disease.

Basic-Jukic N, Kes P, Coric M, Basic-Kes V.

Curr Pharm Des. 2013;19(33):6046-50. Review.

PMID:
23448456
5.

Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.

Lidove O, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores GM, Mehta A.

Genet Med. 2010 Nov;12(11):668-79. doi: 10.1097/GIM.0b013e3181f13b75. Review.

PMID:
20962662
6.

Cutaneous complications of Anderson-Fabry disease.

Giuseppe P, Daniele R, Rita BM.

Curr Pharm Des. 2013;19(33):6031-6. Review.

PMID:
23448454
7.

Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa.

Ramaswami U.

Acta Paediatr. 2008 Apr;97(457):38-40. doi: 10.1111/j.1651-2227.2008.00658.x. Review.

PMID:
18339186
8.

Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature.

Pisani A, Visciano B, Roux GD, Sabbatini M, Porto C, Parenti G, Imbriaco M.

Mol Genet Metab. 2012 Nov;107(3):267-75. doi: 10.1016/j.ymgme.2012.08.003. Epub 2012 Aug 11. Review.

PMID:
22963910
9.

Enzyme replacement therapy in Fabry disease: influence on cardiac manifestations.

Caballero L, Climent V, Hernández-Romero D, Quintanilla MA, de la Morena G, Marín F.

Curr Med Chem. 2010;17(16):1679-89. Review.

PMID:
20345350
10.

Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.

Putko BN, Wen K, Thompson RB, Mullen J, Shanks M, Yogasundaram H, Sergi C, Oudit GY.

Heart Fail Rev. 2015 Mar;20(2):179-91. doi: 10.1007/s10741-014-9452-9. Review.

PMID:
25030479
11.

Fabry disease, enzyme replacement therapy and the significance of antibody responses.

Deegan PB.

J Inherit Metab Dis. 2012 Mar;35(2):227-43. doi: 10.1007/s10545-011-9400-y. Epub 2011 Oct 25. Review.

PMID:
22037707
12.

[Clinical efficacy of enzyme replacement therapy in Fabry disease. A critical review].

Lidove O, Papo T.

Rev Med Interne. 2009 Oct;30(10):920-9. doi: 10.1016/j.revmed.2009.04.003. Epub 2009 Jun 12. Review. French.

PMID:
19524334
13.

Anderson-Fabry disease: developments in diagnosis and treatment.

Mehta AB.

Int J Clin Pharmacol Ther. 2009;47 Suppl 1:S66-74. Review.

PMID:
20040315
14.

Enzyme replacement therapy for Anderson-Fabry disease.

El Dib RP, Pastores GM.

Cochrane Database Syst Rev. 2010 May 12;(5):CD006663. doi: 10.1002/14651858.CD006663.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;2:CD006663.

PMID:
20464743
15.

Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature.

Lidove O, Joly D, Barbey F, Bekri S, Alexandra JF, Peigne V, Jaussaud R, Papo T.

Int J Clin Pract. 2007 Feb;61(2):293-302. Review.

PMID:
17263716
16.

Gastroenterological complications of Anderson-Fabry disease.

Buda P, Książyk J, Tylki-Szymanska A.

Curr Pharm Des. 2013;19(33):6009-13. Review.

PMID:
23448457
17.

Fabry disease.

Tarabuso AL.

Skinmed. 2011 May-Jun;9(3):173-7. Review.

PMID:
21675497
18.

Efficacy of enzyme replacement therapy in Fabry disease.

Barbey F, Hayoz D, Widmer U, Burnier M.

Curr Med Chem Cardiovasc Hematol Agents. 2004 Oct;2(4):277-86. Review.

PMID:
15320778
19.

The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.

Morel CF, Clarke JT.

Expert Opin Biol Ther. 2009 May;9(5):631-9. doi: 10.1517/14712590902902296 . Review.

PMID:
19368525
20.

A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1.

Connock M, Juarez-Garcia A, Frew E, Mans A, Dretzke J, Fry-Smith A, Moore D.

Health Technol Assess. 2006 Jun;10(20):iii-iv, ix-113. Review.

Items per page

Supplemental Content

Write to the Help Desk